Payor concentration and reimbursement dependence
A significant portion of revenue comes from a small number of third-party payors, so coverage or pricing changes can quickly affect revenue.
- Scope
- Medicare and commercial payors
- Materiality
- high
Castle Biosciences, Inc
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in dermatology, gastroenterology, and ophthalmology. Its portfolio is centered on proprietary multi-analyte assays with algorithmic analysis (MAAA), which turn patient tissue samples into clinically actionable risk and treatment information. The company’s commercial focus has expanded from dermatologic cancers into Barrett’s esophagus, uveal melanoma, and atopic dermatitis. Revenue is generated primarily through reimbursement from third-party payors for tests performed in its CLIA-certified laboratories.
−0,6 %
79,4 %
−7,0 %
+3,7 %
5.26
5.11
| % | |
|---|---|
| Dermatologic cancer tests | 63% Molecular tests used in melanoma and squamous cell carcinoma to help guide diagnosis, staging, and treatment decisions. |
| Gastroenterology tests | 25% TissueCypher testing for Barrett’s esophagus risk stratification and management support. |
| Ophthalmology tests | 8% DecisionDx-UM testing for uveal melanoma prognosis and treatment planning. |
| Atopic dermatitis test | 4% AdvanceAD-Tx, a test intended to guide systemic treatment decisions in moderate-to-severe atopic dermatitis. |
Castle Biosciences sells primarily to clinicians and associated medical staff who order molecular tests to support...
- U.S. dermatology practicesprimary
Buy DecisionDx-Melanoma, DecisionDx-SCC and MyPath Melanoma to improve risk stratification and treatment planning for skin cancer patients.
- Gastroenterology practicesprimary
Buy TissueCypher to assess Barrett’s esophagus progression risk and guide surveillance or intervention decisions.
- Ophthalmology and ocular oncology centerssecondary
Buy DecisionDx-UM to support prognosis and management decisions for uveal melanoma.
- Atopic dermatitis specialistsemerging
Buy AdvanceAD-Tx to help guide systemic treatment choices in moderate-to-severe AD.
- Third-party payorsprimary
Do not buy the tests directly, but their coverage decisions determine whether Castle can convert clinical adoption into reimbursed revenue.
Castle Biosciences is operationally centered in the United States, where it generates essentially all of its commercial...
- •United States is the core commercial market for all major tests
- •Laboratories operated in Phoenix, Arizona and Pittsburgh, Pennsylvania
- •CLIA and CAP accreditation support nationwide testing operations
- •New York State approval is relevant for certain proprietary tests
- •State-by-state licensing affects where tests can be marketed and billed
- •No meaningful international operating footprint is disclosed
Castle Biosciences is focused on expanding reimbursement and clinical adoption for its molecular tests, because payor...
01
Expand reimbursement coverageshort-term
Coverage by Medicare and commercial payors is essential because most revenue comes from reimbursed testing rather than direct consumer sales.
02
Increase clinician adoption through sales and medical affairsshort-term
The company’s tests require education on clinical utility, so field engagement directly affects test volumes.
03
Develop and validate new productsmedium-term
Pipeline expansion is needed to diversify revenue and create future reimbursable tests in adjacent specialties.
04
Integrate acquisitions and scale operationsmedium-term
Acquired assets can add revenue, but only if integrated efficiently into the existing commercial and laboratory platform.
Castle Biosciences is exposed to reimbursement risk because a large share of revenue depends on a relatively small...
Coverage loss for specific tests
The 2025 loss of Medicare LCD coverage for DecisionDx-SCC reduced realized pricing and revenue contribution.
- Scope
- DecisionDx-SCC
- Materiality
- high
Clinical adoption and competitive pressure
Demand depends on clinicians preferring Castle’s tests over traditional staging criteria or competing assays.
- Scope
- Dermatology and uveal melanoma testing
- Materiality
- medium
Acquisition integration risk
Integrating acquired products and operations can distract management and create cost, execution, and retention issues.
- Scope
- TissueCypher and prior acquisitions
- Materiality
- medium
Regulatory and laboratory compliance
Testing operations require CLIA, CAP, and state approvals, and noncompliance could restrict operations or billing.
- Scope
- Phoenix and Pittsburgh labs; multi-state operations
- Materiality
- medium
Revenue recognition and reimbursement estimates
Can materially affect reported revenue and accounts receivable
Quarterly volume and payer-mix volatility
Creates uneven quarterly revenue and margin trends
Goodwill and intangible asset impairment
Potential non-cash charges to earnings
Acquisition-related amortization
Reduces reported operating income
Research and development expense recognition
Can suppress near-term profitability during pipeline investment cycles
: 11/08/2026